Hongmei Jing

机构：Peking University, Peking University Third Hospital · ORCID：0009-0002-7352-3964

发表论文 35 篇 · 总被引 79 次 · h-index 5

代表论文

• Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study (2024 · Journal of Hematology & Oncology · 被引 16)
• Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE (2024 · Annals of Hematology · 被引 8)
• Preliminary results from a phase I/II study of IMM0306, a CD47 and CD20 bispecific monoclonal antibody-trap, in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma. (2023 · Journal of Clinical Oncology · 被引 5)
• Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease (2024 · Cancer Pathogenesis and Therapy · 被引 4)
• Prediction and prognostic potential of NR3C1 gene expression level in DLBCL patients (2023 · Hematology · 被引 4)
• The immune landscape and viral shedding of Omicron SARS-CoV-2 variants implicate immune escape (2025 · Frontiers in Medicine · 被引 2)